|
參考文獻 Ambudkar, S.V., Dey, S., Hrycyna, C.A., Ramachandra, M., Pastan, I. and Gottesman, M.M. (1999) Biochemical, cellular, and pharmacological aspects of the multidrug transporter. Annu Rev Pharmacol Toxicol 39, 361-98. Bech-Hansen, N.T., Till, J.E. and Ling, V. (1976) Pleiotropic phenotype of colchicine-resistant CHO cells: cross- resistance and collateral sensitivity. J Cell Physiol 88, 23-31. Biedler, J.L. and Riehm, H. (1970) Cellular resistance to actinomycin D in Chinese hamster cells in vitro: cross-resistance, radioautographic, and cytogenetic studies. Cancer Res 30, 1174-84. Boer, R., Gekeler, V., Ulrich, W.R., Zimmermann, P., Ise, W., Schodl, A. and Haas, S. (1996) Modulation of P-glycoprotein mediated drug accumulation in multidrug resistant CCRF VCR-1000 cells by chemosensitisers. Eur J Cancer 32A, 857-61. Borst, P. (1997) Multidrug resistant proteins. Semin Cancer Biol 8, 131-4. Borst, P. and Schinkel, A.H. (1997) Genetic dissection of the function of mammalian P-glycoproteins. Trends Genet 13, 217-22. Chen, C.J., Chin, J.E., Ueda, K., Clark, D.P., Pastan, I., Gottesman, M.M. and Roninson, I.B. (1986) Internal duplication and homology with bacterial transport proteins in the mdr1 (P-glycoprotein) gene from multidrug-resistant human cells. Cell 47, 381-9. Chen, C.J., Clark, D., Ueda, K., Pastan, I., Gottesman, M.M. and Roninson, I.B. (1990) Genomic organization of the human multidrug resistance (MDR1) gene and origin of P-glycoproteins. J Biol Chem 265, 506-14. Cordon-Cardo, C., O'Brien, J.P., Boccia, J., Casals, D., Bertino, J.R. and Melamed, M.R. (1990) Expression of the multidrug resistance gene product (P-glycoprotein) in human normal and tumor tissues. J Histochem Cytochem 38, 1277-87. Daoud, R., Kast, C., Gros, P. and Georges, E. (2000) Rhodamine 123 binds to multiple sites in the multidrug resistance protein (MRP1). Biochemistry 39, 15344-52. Fisher, G.A., Lum, B.L., Hausdorff, J. and Sikic, B.I. (1996) Pharmacological considerations in the modulation of multidrug resistance. Eur J Cancer 32A, 1082-8. Fojo, A., Akiyama, S., Gottesman, M.M. and Pastan, I. (1985) Reduced drug accumulation in multiply drug-resistant human KB carcinoma cell lines. Cancer Res 45, 3002-7. Ford, J.M. (1995) Modulators of multidrug resistance. Preclinical studies. Hematol Oncol Clin North Am 9, 337-61. Gengo, F.M., Dabronzo, J., Yurchak, A., Love, S. and Miller, J.K. (1987) The relative antihistaminic and psychomotor effects of hydroxyzine and cetirizine. Clin Pharmacol Ther 42, 265-72. Germann, U.A., Ford, P.J., Shlyakhter, D., Mason, V.S. and Harding, M.W. (1997) Chemosensitization and drug accumulation effects of VX-710, verapamil, cyclosporin A, MS-209 and GF120918 in multidrug resistant HL60/ADR cells expressing the multidrug resistance-associated protein MRP. Anticancer Drugs 8, 141-55. Greenberger, L.M. (1993) Major photoaffinity drug labeling sites for iodoaryl azidoprazosin in P- glycoprotein are within, or immediately C-terminal to, transmembrane domains 6 and 12. J Biol Chem 268, 11417-25. Higgins, C.F. and Gottesma, M.M. (1992) Is the multidrug transporter a flippase? Trends Biochem Sci 17, 18-21. Hirsch-Ernst, K.I., Ziemann, C., Rustenbeck, I. and Kahl, G.F. (2001) Inhibitors of mdr1-dependent transport activity delay accumulation of the mdr1 substrate rhodamine 123 in primary rat hepatocyte cultures. Toxicology 167, 47-57. Hori, R., Okamura, N., Aiba, T. and Tanigawara, Y. (1993) Role of P-glycoprotein in renal tubular secretion of digoxin in the isolated perfused rat kidney. J Pharmacol Exp Ther 266, 1620-5. Hsu, S.I., Lothstein, L. and Horwitz, S.B. (1989) Differential overexpression of three mdr gene family members in multidrug-resistant J774.2 mouse cells. Evidence that distinct P- glycoprotein precursors are encoded by unique mdr genes. J Biol Chem 264, 12053-62. Hyde, S.C., Emsley, P., Hartshorn, M.J., Mimmack, M.M., Gileadi, U., Pearce, S.R., Gallagher, M.P., Gill, D.R., Hubbard, R.E. and Higgins, C.F. (1990) Structural model of ATP-binding proteins associated with cystic fibrosis, multidrug resistance and bacterial transport. Nature 346, 362-5. Johnson, L.V., Walsh, M.L. and Chen, L.B. (1980) Localization of mitochondria in living cells with rhodamine 123. Proc Natl Acad Sci U S A 77, 990-4. Juliano, R.L. and Ling, V. (1976) A surface glycoprotein modulating drug permeability in Chinese hamster ovary cell mutants. Biochim Biophys Acta 455, 152-62. Kan, W.M., Liu, Y.T., Hsiao, C.L., Shieh, C.Y., Kuo, J.H., Huang, J.D. and Su, S.F. (2001) Effect of hydroxyzine on the transport of etoposide in rat small intestine. Anticancer Drugs 12, 267-73. Kusunoki, N., Takara, K., Tanigawara, Y., Yamauchi, A., Ueda, K., Komada, F., Ku, Y., Kuroda, Y., Saitoh, Y. and Okumura, K. (1998) Inhibitory effects of a cyclosporin derivative, SDZ PSC 833, on transport of doxorubicin and vinblastine via human P-glycoprotein. Jpn J Cancer Res 89, 1220-8. Lincke, C.R., Smit, J.J., van der Velde-Koerts, T. and Borst, P. (1991) Structure of the human MDR3 gene and physical mapping of the human MDR locus. J Biol Chem 266, 5303-10. Loo, T.W. and Clarke, D.M. (1994) Reconstitution of drug-stimulated ATPase activity following co- expression of each half of human P-glycoprotein as separate polypeptides. J Biol Chem 269, 7750-5. Loo, T.W. and Clarke, D.M. (1995) Rapid purification of human P-glycoprotein mutants expressed transiently in HEK 293 cells by nickel-chelate chromatography and characterization of their drug-stimulated ATPase activities. J Biol Chem 270, 21449-52. Lum, B.L., Fisher, G.A., Brophy, N.A., Yahanda, A.M., Adler, K.M., Kaubisch, S., Halsey, J. and Sikic, B.I. (1993) Clinical trials of modulation of multidrug resistance. Pharmacokinetic and pharmacodynamic considerations. Cancer 72, 3502-14. Martin, C., Berridge, G., Higgins, C.F., Mistry, P., Charlton, P. and Callaghan, R. (2000) Communication between multiple drug binding sites on P-glycoprotein. Mol Pharmacol 58, 624-32. Ozols, R.F., Cunnion, R.E., Klecker, R.W., Jr., Hamilton, T.C., Ostchega, Y., Parrillo, J.E. and Young, R.C. (1987) Verapamil and adriamycin in the treatment of drug-resistant ovarian cancer patients. J Clin Oncol 5, 641-7. Paton, D.M. and Webster, D.R. (1985) Clinical pharmacokinetics of H1-receptor antagonists (the antihistamines). Clin Pharmacokinet 10, 477-97. Pawagi, A.B., Wang, J., Silverman, M., Reithmeier, R.A. and Deber, C.M. (1994) Transmembrane aromatic amino acid distribution in P-glycoprotein. A functional role in broad substrate specificity. J Mol Biol 235, 554-64. Rao, V.V., Dahlheimer, J.L., Bardgett, M.E., Snyder, A.Z., Finch, R.A., Sartorelli, A.C. and Piwnica-Worms, D. (1999) Choroid plexus epithelial expression of MDR1 P glycoprotein and multidrug resistance-associated protein contribute to the blood- cerebrospinal-fluid drug-permeability barrier. Proc Natl Acad Sci U S A 96, 3900-5. Robert, J. (1999) Multidrug resistance in oncology: diagnostic and therapeutic approaches. Eur J Clin Invest 29, 536-45. Sand, A.E., Ostlund, E., Andersson, E. and Fried, G. (1998) Endothelin-induced contractions in placental arteries is mediated by both ETA- and ETB-receptors. Acta Physiol Scand 163, 227-34. Schinkel, A.H., Smit, J.J., van Tellingen, O., Beijnen, J.H., Wagenaar, E., van Deemter, L., Mol, C.A., van der Valk, M.A., Robanus-Maandag, E.C., te Riele, H.P. and et al. (1994) Disruption of the mouse mdr1a P-glycoprotein gene leads to a deficiency in the blood-brain barrier and to increased sensitivity to drugs. Cell 77, 491-502. Schinkel, A.H., Wagenaar, E., Mol, C.A. and van Deemter, L. (1996) P-glycoprotein in the blood-brain barrier of mice influences the brain penetration and pharmacological activity of many drugs. J Clin Invest 97, 2517-24. Shapiro, A.B., Corder, A.B. and Ling, V. (1997) P-glycoprotein-mediated Hoechst 33342 transport out of the lipid bilayer. Eur J Biochem 250, 115-21. Shapiro, A.B., Fox, K., Lam, P. and Ling, V. (1999) Stimulation of P-glycoprotein-mediated drug transport by prazosin and progesterone. Evidence for a third drug-binding site. Eur J Biochem 259, 841-50. Shapiro, A.B. and Ling, V. (1997) Positively cooperative sites for drug transport by P-glycoprotein with distinct drug specificities. Eur J Biochem 250, 130-7. Simons, F.E. (1990) Recent advances in H1-receptor antagonist treatment. J Allergy Clin Immunol 86, 995-9. Simons, F.E. and Simons, K.J. (1991) Pharmacokinetic optimisation of histamine H1-receptor antagonist therapy. Clin Pharmacokinet 21, 372-93. Simons, F.E., Simons, K.J., Chung, M. and Yeh, J. (1987) The comparative pharmacokinetics of H1-receptor antagonists. Ann Allergy 59, 20-4. Simons, F.E., Simons, K.J. and Frith, E.M. (1984) The pharmacokinetics and antihistaminic of the H1 receptor antagonist hydroxyzine. J Allergy Clin Immunol 73, 69-75. Stapf, V., Thalhammer, T., Huber-Huber, R., Felberbauer, F., Gajdzik, L. and Graf, J. (1994) Inhibition of rhodamine 123 secretion by cyclosporin A as a model of P- glycoprotein mediated transport in liver. Anticancer Res 14, 581-5. Stouch, T.R. and Gudmundsson, O. (2002) Progress in understanding the structure-activity relationships of P- glycoprotein. Adv Drug Deliv Rev 54, 315-28. Takada, Y., Yamada, K., Taguchi, Y., Kino, K., Matsuo, M., Tucker, S.J., Komano, T., Amachi, T. and Ueda, K. (1998) Non-equivalent cooperation between the two nucleotide-binding folds of P-glycoprotein. Biochim Biophys Acta 1373, 131-6. Tamai, I. and Safa, A.R. (1991) Azidopine noncompetitively interacts with vinblastine and cyclosporin A binding to P-glycoprotein in multidrug resistant cells. J Biol Chem 266, 16796-800. Tan, B., Piwnica-Worms, D. and Ratner, L. (2000) Multidrug resistance transporters and modulation. Curr Opin Oncol 12, 450-8. Tanigawara, Y. (2000) Role of P-glycoprotein in drug disposition. Ther Drug Monit 22, 137-40. Traunecker, H.C., Stevens, M.C., Kerr, D.J. and Ferry, D.R. (1999) The acridonecarboxamide GF120918 potently reverses P-glycoprotein- mediated resistance in human sarcoma MES-Dx5 cells. Br J Cancer 81, 942-51. Tsuruo, T., Iida, H., Tsukagoshi, S. and Sakurai, Y. (1981) Overcoming of vincristine resistance in P388 leukemia in vivo and in vitro through enhanced cytotoxicity of vincristine and vinblastine by verapamil. Cancer Res 41, 1967-72. Ueda, K., Clark, D.P., Chen, C.J., Roninson, I.B., Gottesman, M.M. and Pastan, I. (1987) The human multidrug resistance (mdr1) gene. cDNA cloning and transcription initiation. J Biol Chem 262, 505-8. Ueda, K., Yoshida, A. and Amachi, T. (1999) Recent progress in P-glycoprotein research. Anticancer Drug Des 14, 115-21. Urbatsch, I.L., Sankaran, B., Bhagat, S. and Senior, A.E. (1995) Both P-glycoprotein nucleotide-binding sites are catalytically active. J Biol Chem 270, 26956-61. van der Bliek, A.M., Kooiman, P.M., Schneider, C. and Borst, P. (1988) Sequence of mdr3 cDNA encoding a human P-glycoprotein. Gene 71, 401-11. Wacher, V.J., Wu, C.Y. and Benet, L.Z. (1995) Overlapping substrate specificities and tissue distribution of cytochrome P450 3A and P-glycoprotein: implications for drug delivery and activity in cancer chemotherapy. Mol Carcinog 13, 129-34. Wood, S.G., John, B.A., Chasseaud, L.F., Yeh, J. and Chung, M. (1987) The metabolism and pharmacokinetics of 14C-cetirizine in humans. Ann Allergy 59, 31-4. Zeng, H., Bain, L.J., Belinsky, M.G. and Kruh, G.D. (1999) Expression of multidrug resistance protein-3 (multispecific organic anion transporter-D) in human embryonic kidney 293 cells confers resistance to anticancer agents. Cancer Res 59, 5964-7.
|